These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38238945)

  • 1. [Current status and treatment strategies for liver injury before targeted immunotherapy for liver cancer].
    Jia JM; Ren JS; Zhang LY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1133-1136. PubMed ID: 38238945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Research progress of immunotherapy alone and in combination for liver cancer].
    Wu ZJL; Li K; Zhang K; Gong WD
    Zhonghua Gan Zang Bing Za Zhi; 2020 Jun; 28(6):471-474. PubMed ID: 32660173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Strategies for liver injury caused by hepatocellular carcinoma targeted therapy].
    Zhao SX; Liu SH; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1129-1132. PubMed ID: 38238944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bibliometric study of immunotherapy for hepatocellular carcinoma.
    Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H
    Front Immunol; 2023; 14():1210802. PubMed ID: 37600802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma].
    Zhang DZ; Niu JQ
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):834-837. PubMed ID: 31941237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress in immunotherapy for hepatocellular carcinoma].
    Shen Z; Li M; Bai S; Yang Q; Zhang F; Tang M; Guo J; Yang Z
    Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2326-2338. PubMed ID: 31880139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Liver cancer immunotherapy in the context of precision medicine].
    Huan HB; Chen XJ; Xia F
    Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):910-914. PubMed ID: 33256274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The companion diagnostics of targeted therapy and immunotherapy for hepatocellular carcinoma].
    Huang XW; Liu SH; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2022 Sep; 30(9):912-917. PubMed ID: 36299182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].
    Li R; Li WL; Yuan GS; Pang HJ; Li Q; Hu XY; Guo YB; Chen JZ; Zang MY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1163-1168. PubMed ID: 38238949
    [No Abstract]   [Full Text] [Related]  

  • 11. [Advances in the study of cellular immunotherapy for liver cancer].
    Su S; Huang XW
    Zhonghua Gan Zang Bing Za Zhi; 2020 Jun; 28(6):461-465. PubMed ID: 32660171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report.
    Wang Y; Zhao Y; Li M; Hou H; Jian Z; Li W; Li P; Ma F; Liu M; Liu H; Xue H
    Front Immunol; 2023; 14():1180001. PubMed ID: 37256142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Hepatocellular carcinoma: A life-threatening disease".
    Chacko S; Samanta S
    Biomed Pharmacother; 2016 Dec; 84():1679-1688. PubMed ID: 27823920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for hepatocellular carcinoma.
    Li S; Yang F; Ren X
    Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features and prognostic analysis of transarterial chemoembolization combined with targeted immunotherapy in the treatment of patients with hepatitis B virus-related intermediate-and advanced-stage hepatocellular carcinoma with secondary cholestasis].
    Wang NN; Shen JM; Li HL; Wang X; Yang GD; Pan XC; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1149-1155. PubMed ID: 38238947
    [No Abstract]   [Full Text] [Related]  

  • 16. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.
    Zhou H; Song T
    Biosci Trends; 2021 Jul; 15(3):155-160. PubMed ID: 34039818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for hepatocellular carcinoma.
    Zhou M; Liu B; Shen J
    Clin Exp Med; 2023 Jul; 23(3):569-577. PubMed ID: 36001163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy.
    Nikoo M; Hassan ZF; Mardasi M; Rostamnezhad E; Roozbahani F; Rahimi S; Mohammadi J
    Pathol Res Pract; 2023 Jul; 247():154473. PubMed ID: 37207558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
    Majumdar A; Roccarina D; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011650. PubMed ID: 28351116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiality of immunotherapy against hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.